The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil

  title={The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil},
  author={Walther Birkmayer and Peter Franz Riederer and Moussa B. H. Youdim and W. Linauer},
  journal={Journal of Neural Transmission},
The potentiation of the ami akinetic effect after L-Dopa treatment by an inhibitor of monoamine oxidase (MAO) “B”, Deprenil, has been demonstrated in parkinsonian patients with or without previous L-Dopa therapy. Application of the drug has been performed orally, intravenously and intramuscularly. Excellent kinetic effects resulted when combined with Madopar. The combined treatment with L-Dopa was highly effective when applicated i.v. or i.m. Deprenil is an inhibitor of MAO-B and is… 

The clinical and biochemical investigation of L-deprenyl in Parkinson's disease with special reference to the “on-off” effect

The effect of L-deprenyl in combination with L-Dopa was studied in 22 Parkinsonian patients, with various forms of “on-off” phenomena, and the results were very encouraging with regard to amelioration of ” on-off effect”.

On the mode of action of L-deprenyl in the human central nervous system

In vitro studies demonstrated that (-)deprenyl in comparison to d, l-tranylcypromine, clorgyline and harmaline is by far the most potent inhibitor of human brain MAO, and long-term treatment with more than 1 mg/10 kg body weight could result in an accumulation of (-)DeprenylIn the brain.

The possible mechanisms of action of (-)deprenyl in Parkinson's disease

  • J. Knoll
  • Biology, Chemistry
    Journal of Neural Transmission
  • 2005
The advantage of the combination of levodopa and (-)deprenyl in the treatment of Parkinson's disease was summarized as follows.

Long term treatment with L-deprenyl

The aim of this presentation is to compare the clinical effect of a long-term medication of Madopar (L-Dopa plus the peripherally acting decarboxylase inhibitor benserazide) with the combined medication ofMadopar plus L-deprenyl.

Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm study

Results are interpreted as indicating l-deprenyl's ability to prevent or retard the degeneration of striatal dopaminergic neurons, the first anti-Parkinson drug having such a property.

Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition

Because of their selective action on the specific forms ofMAO, which results in selective elevation of brain noradrenaline and serotonin on the one hand and dopamine and phenylethylamine on the other, it is hoped that these drugs will be able to elucidate the functional roles of MAO-A and B subtypes with regards to dopamine metabolism in the human brain.

L-deprenyl treatment of on-off phenomena in Parkinson's disease

It was concluded that L-deprenyl seems to provide a valuable adjuvant to levodopa in patients with on-off disabilities.

Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology

The clinical potential of MAO inhibitors together with detailed knowledge of the enzyme's binding site structure should lead to future developments with these drugs.

MAO-inhibitors in Parkinson's Disease

In general, the clinical use of MAO-I nowadays is underestimated and there should be more efforts to evaluate their clinical potency as antidepressants and antidementive drugs in addition to the final proof of their disease-modifying potential.

Effect of monoamine oxidase A and B and of catechol-O-methyltransferase inhibition on L-DOPA-induced circling behavior

The effect of enzyme-inhibiting adjuvants on L-DOPA + benserazide-induced contralateral turning in unilateral 6-hydroxydopamine-lesioned rats was studied and a further potentiation of turning behavior was observed after the combined administration of both the MAO-A and COMT inhibitor.



Die moderne medikamentöse Behandlung des Parkinsonismus

The administration of L-DCPA effected an improvement in the akinesia for a short time only, and a combination of l-DOPA with a decarboxylase inhibitor (Ro4-4602) produced a more intensive effect over a longer period.

L-dopa level in plasma, primary condition for the kinetic effect

For producing kinetic effects a sufficient availability of L-Dopa in plasma is necessary and a sufficient utilization in the brain has to be and in cases of akinetic crisis a combined infusion of L ofopa plus amantadine-sulfate is a vital indication.

Monoamine oxidase. Its inhibition.

There is now a revival of interest in the functional role of MAO in the central nervous system and drugs that inhibit or stimulate its activity "specifically", and the advent of new drugs with "selective" inhibition of enzyme forms.

Effect of Pretreatment with Oestradiol, Progesterone and DOPA on Monoamine Oxidase Activity in the Rat

To investigate the possibility that physiologically occurring cyclical increases in MAO activity might represent an adaptive response to increased availability of substrate, it is attempted to evaluate this possibility indirectly by treating rats before enzyme assay with DOPA which leads to increased tissue levels of the MAO substrate, dopamine.

Biological Sciences: Human Brain Monoamine Oxidase: Multiple Forms and Selective Inhibitors

An explanation might be sought in terms of differential inhibitory capacity of these drugs on the four molecular variants of MAO in the human brain on the basis of differing ability of the MAO inhibitors to prevent amine re-uptake.

“On‐off” phenomenon with levodopa therapy in parkinsonism

  • S. Fahn
  • Psychology, Medicine
  • 1974
Serial half-hourly measurements of plasma levels of dopa, 3-O-methyldopa, and homovanillic acid showed partial concordance between clinical fluctuation and plasma dopa levels in patients receiving levodopa alone or in combination with carbidopa.

Corticosteroid and growth hormone secretion in patients treated with L-dopa

This preliminary study provides support for the hypothesis of a central adrenergic neural system inhibiting ACTH secretion in man by evaluating urinary steroid determinations and measurements of plasma 11-hydroxycorticosteroid and serum growth hormone responses to insulin hypoglycemia before and during treatment with L-dopa.

Changes in the concentration and intracellular distribution of brain catecholamines: the effects of reserpine. beta-phenyliso-propylhydrazine, pyrogallol and 3,4-dihydroxyphenyl alanine, alone and in combination.

The effects of Catron, dopa and Catron + dopa were also studied in animals whose brain catecholamine stores had previously been depleted by reserpine, and the effects were similar to those observed in normal brains.

Dopamine and basal ganglia diseases.

  • A. Barbeau
  • Medicine, Biology
    Archives of neurology
  • 1961
Recent developments in biochemical changes in mental disease, especially alterations in catechol-amine and serotonin metabolism, are becoming increasingly important, and it may be that the present findings will give some recent developments in this field the attention of neurologists.

Relation of sex and aging to monoamine oxidase activity of human brain, plasma, and platelets.

Increased enzyme activity related to aging and sex may be a biologic factor that, in association with Psychological and social stresses, predisposes certain individuals to the development of depression.